abs67.txt	importance		localized	prostate	cancer	diagnosis	and	treatment	among	elderly	menwho	are	not	likely	to	benefit	represents	a	potential	source	of	low-value	healthcare	services	objective		to	quantify	the	costs	to	the	medicare	program	associated	withdetection	and	treatment	of	prostate	cancer	among	elderly	men	in	the	unitedstates	design		setting		and	participants		this	nationwide		population-based	retrospective	cohort	study	uses	the	surveillance		epidemiology		and	end	results(seer)-medicare	linked	database	to	identify	men	70	years	or	older	diagnosed	withlocalized	prostate	cancer	between	2004	and	2007	and	to	ascertain	medicare	costsassociated	with	diagnosis	and	workup		treatment		follow-up		and	morbiditymanagement	of	the	disease		national	medicare	costs	were	estimated	usingper-person	costs		stage-adjusted	prostate	cancer	incidence	rates	by	age	from	seer2007	through	2011		and	2010	census	population	estimates	by	age	main	outcomes	and	measures		estimated	costs	to	the	medicare	program	overall		andin	each	(mutually	exclusive)	category	related	to	diagnosis	and	workup		treatment	follow-up		and	morbidity	management	results		this	nationwide		population-based		retrospective	cohort	study	included49	692	men	with	nonmetastatic	prostate	cancer	from	the	seer-medicare	database(all	participants	were	70	years	or	older		25	981	[52	3%]	were	76	years	or	older)	the	median	per-patient	cost	within	3	years	after	prostate	cancer	diagnosis	was$14	453	(interquartile	range	[iqr]		$4887-$27	899)		the	majority	of	this	cost	wasattributable	to	treatment	costs	(median		$10	558		iqr		$1990-$23	718)		patientswith	a	gleason	score	of	6	or	lower	who	pursued	initial	conservative	management(no	treatment	within	12	months	of	diagnosis)	had	a	3-year	median	total	cost	of$1914	per	patient		the	estimated	total	3-year	cost	to	the	medicare	programassociated	with	the	annual	detection	of	prostate	cancer	in	men	70	years	or	olderis	approximately	$1	2	billion		increasing	active	surveillance	use	in	those	withgleason	score	of	6	or	lower	could	reduce	this	cost	by	$320	million	conclusions	and	relevance		there	is	substantial	cost	to	the	medicare	programassociated	with	the	diagnosis	and	treatment	of	localized	prostate	cancer	amongelderly	men	in	the	united	states		despite	the	fact	that	these	men	are	unlikely	todie	of	prostate	cancer		the	majority	of	costs	are	related	to	treatment		reducingprovision	of	low-value	health	care	services	among	this	patient	population	couldresult	in	significant	health	care	savings	
